These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
533 related articles for article (PubMed ID: 12017378)
41. Relationship between dose-intensity of treatment and outcome for patients with osteosarcoma of the extremity treated with neoadjuvant chemotherapy. Bacci G; Ferrari S; Longhi A; Forni C; Giacomini S; Lari S; Versari M Oncol Rep; 2001; 8(4):883-8. PubMed ID: 11410803 [TBL] [Abstract][Full Text] [Related]
42. Long-term results of the co-operative German-Austrian-Swiss osteosarcoma study group's protocol COSS-86 of intensive multidrug chemotherapy and surgery for osteosarcoma of the limbs. Fuchs N; Bielack SS; Epler D; Bieling P; Delling G; Körholz D; Graf N; Heise U; Jürgens H; Kotz R; Salzer-Kuntschik M; Weinel P; Werner M; Winkler K Ann Oncol; 1998 Aug; 9(8):893-9. PubMed ID: 9789613 [TBL] [Abstract][Full Text] [Related]
43. Zoledronate in combination with chemotherapy and surgery to treat osteosarcoma (OS2006): a randomised, multicentre, open-label, phase 3 trial. Piperno-Neumann S; Le Deley MC; Rédini F; Pacquement H; Marec-Bérard P; Petit P; Brisse H; Lervat C; Gentet JC; Entz-Werlé N; Italiano A; Corradini N; Bompas E; Penel N; Tabone MD; Gomez-Brouchet A; Guinebretière JM; Mascard E; Gouin F; Chevance A; Bonnet N; Blay JY; Brugières L; ; ; Lancet Oncol; 2016 Aug; 17(8):1070-1080. PubMed ID: 27324280 [TBL] [Abstract][Full Text] [Related]
44. SFOP OS94: a randomised trial comparing preoperative high-dose methotrexate plus doxorubicin to high-dose methotrexate plus etoposide and ifosfamide in osteosarcoma patients. Le Deley MC; Guinebretière JM; Gentet JC; Pacquement H; Pichon F; Marec-Bérard P; Entz-Werlé N; Schmitt C; Brugières L; Vanel D; Dupoüy N; Tabone MD; Kalifa C; Eur J Cancer; 2007 Mar; 43(4):752-61. PubMed ID: 17267204 [TBL] [Abstract][Full Text] [Related]
45. Neoadjuvant chemotherapy for nonmetastatic osteosarcoma of the extremities. Bacci G; Picci P; Pignatti G; De Cristofaro R; Dallari D; Avella M; Manfrini M; Marangolo M; Ferruzzi A; Mercuri M Clin Orthop Relat Res; 1991 Sep; (270):87-98. PubMed ID: 1884564 [TBL] [Abstract][Full Text] [Related]
46. Neoadjuvant chemotherapy for osteosarcoma of the extremities. Good response of the primary tumor after preoperative chemotherapy with high-dose methotrexate followed by cisplatinum and adriamycin. Preliminary results. Bacci G; Avella M; Brach Del Prevert A; Capanna R; Fiorentini G; Malaguti C; Picci P; Rosito P; Campanacci M Chemioterapia; 1988 Apr; 7(2):138-42. PubMed ID: 3165058 [TBL] [Abstract][Full Text] [Related]
47. A phase II study of cisplatin, ifosfamide and epirubicin combination chemotherapy in adults with nonmetastatic and extremity osteosarcomas. Basaran M; Bavbek ES; Saglam S; Eralp L; Sakar B; Atalar AC; Bilgic B; Ozger H; Onat H Oncology; 2007; 72(3-4):255-60. PubMed ID: 18185020 [TBL] [Abstract][Full Text] [Related]
48. Neoadjuvant chemotherapy for the treatment of osteosarcoma of the limbs. Preliminary results in 100 patients treated preoperatively with high doses of methotrexate i.v. followed by cisplatin (i.a.) and adriamycin. Bacci G; Picci P; Ruggieri P; Avella M; Mercuri M; Capanna R; Biagini R; Tienghi C; Mancini A; Brach del Prever A Chir Organi Mov; 1991; 76(1):1-16. PubMed ID: 1893781 [TBL] [Abstract][Full Text] [Related]
49. Delayed methotrexate clearance in osteosarcoma patients treated with multiagent regimens of neoadjuvant chemotherapy. Bacci G; Ferrari S; Longhi A; Forni C; Loro L; Beghelli C; Tremosini M; Versari M Oncol Rep; 2003; 10(4):851-7. PubMed ID: 12792734 [TBL] [Abstract][Full Text] [Related]
50. Dose-intense ifosfamide/doxorubicin/cisplatin based chemotherapy for osteosarcoma in adults. Patel SJ; Lynch JW; Johnson T; Carroll RR; Schumacher C; Spanier S; Scarborough M Am J Clin Oncol; 2002 Oct; 25(5):489-95. PubMed ID: 12393991 [TBL] [Abstract][Full Text] [Related]
52. No correlation between methotrexate serum level and histologic response in the pre-operative treatment of extremity osteosarcoma. Bacci G; Loro L; Longhi A; Bertoni F; Bacchini P; Versari M; Picci P; Serra M Anticancer Drugs; 2006 Apr; 17(4):411-5. PubMed ID: 16549998 [TBL] [Abstract][Full Text] [Related]
53. Camrelizumab in combination with doxorubicin, cisplatin, ifosfamide, and methotrexate in neoadjuvant treatment of resectable osteosarcoma: A prospective, single-arm, exploratory phase II trial. Tang Q; Zhang X; Zhu X; Xu H; Song G; Lu J; Wu H; Deng C; Ai F; Zhang Y; Wang J Cancer Med; 2024 Sep; 13(18):e70206. PubMed ID: 39324173 [TBL] [Abstract][Full Text] [Related]
54. Effect of intra-arterial versus intravenous cisplatin in addition to systemic adriamycin and high-dose methotrexate on histologic tumor response of osteosarcoma of the extremities. Bacci G; Picci P; Avella M; Ferrari S; Casadei R; Ruggieri P; Brach del Prevert A; Tienghi A; Battistini A; Mancini A J Chemother; 1992 Jun; 4(3):189-95. PubMed ID: 1517815 [TBL] [Abstract][Full Text] [Related]
55. Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival--a report from the Children's Oncology Group. Meyers PA; Schwartz CL; Krailo MD; Healey JH; Bernstein ML; Betcher D; Ferguson WS; Gebhardt MC; Goorin AM; Harris M; Kleinerman E; Link MP; Nadel H; Nieder M; Siegal GP; Weiner MA; Wells RJ; Womer RB; Grier HE; J Clin Oncol; 2008 Feb; 26(4):633-8. PubMed ID: 18235123 [TBL] [Abstract][Full Text] [Related]
56. Comparative outcome of Thai pediatric osteosarcoma treated with two protocols: the role of high-dose methotrexate (HDMTX) in a single institute experience. Choeyprasert W; Pakakasama S; Sirachainan N; Songdej D; Chuansumrit A; Anurathapan U; Hongeng S; Nartthanarung A Asian Pac J Cancer Prev; 2014; 15(22):9823-9. PubMed ID: 25520112 [TBL] [Abstract][Full Text] [Related]
57. [Intra-arterial neoadjuvant chemotherapy of sarcoma of the extremities]. Graziani G; Priori T; Fiorentini G; Molinari M; Tienghi A Radiol Med; 1990 Oct; 80(4):474-6. PubMed ID: 2173854 [TBL] [Abstract][Full Text] [Related]
58. Received dose and dose-intensity of chemotherapy and outcome in nonmetastatic extremity osteosarcoma. European Osteosarcoma Intergroup. Lewis IJ; Weeden S; Machin D; Stark D; Craft AW J Clin Oncol; 2000 Dec; 18(24):4028-37. PubMed ID: 11118463 [TBL] [Abstract][Full Text] [Related]
59. The importance of dose-intensity in neoadjuvant chemotherapy of osteosarcoma: a retrospective analysis of high-dose methotrexate, cisplatinum and adriamycin used preoperatively. Bacci G; Picci P; Avella M; Dallari D; Ferrari S; Prasad R; Di Scioscio M; Malaguti C; Caldora P J Chemother; 1990 Apr; 2(2):127-35. PubMed ID: 2362188 [TBL] [Abstract][Full Text] [Related]